Umer Raffat
Stock Analyst at Evercore ISI Group
(1.49)
# 3,572
Out of 5,241 analysts
21
Total ratings
58.82%
Success rate
-3.69%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reinstates: Outperform | n/a | $192.95 | - | 1 | May 15, 2026 | |
| KLRA Kailera Therapeutics | Initiates: Outperform | n/a | $21.04 | - | 1 | May 12, 2026 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $74.92 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $13.29 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $0.86 | - | 1 | Feb 28, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $37.48 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $39.60 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $34.29 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $11.87 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $27.38 | - | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $27.55 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.40 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.02 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $960 | $14.63 | +6,461.86% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $326.31 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $6.33 | +658.29% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $228.77 | - | 1 | Feb 23, 2017 |
Biogen
May 15, 2026
Reinstates: Outperform
Price Target: n/a
Current: $192.95
Upside: -
Kailera Therapeutics
May 12, 2026
Initiates: Outperform
Price Target: n/a
Current: $21.04
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $74.92
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $13.29
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.86
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $37.48
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $39.60
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $34.29
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $11.87
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.38
Upside: -
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $27.55
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.40
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $37.02
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $960
Current: $14.63
Upside: +6,461.86%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $326.31
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $6.33
Upside: +658.29%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $228.77
Upside: -